Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Public ClinicalTrials.gov record NCT06119217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma
Study identification
- NCT ID
- NCT06119217
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Enrollment
- 194 participants
Conditions and interventions
Conditions
Interventions
- Nab-Paclitaxel and gemcitabine Combination Product
- TTX-030, budigalimab, nab-paclitaxel and gemcitabine Combination Product
- TTX-030, nab-paclitaxel and gemcitabine Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2024
- Primary completion
- Jan 31, 2027
- Completion
- May 31, 2027
- Last update posted
- Dec 3, 2024
2024 – 2027
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Tucson | Arizona | 85704 | — |
| Investigative SIte | Hot Springs | Arkansas | 71913 | — |
| Investigative Site | Bakersfield | California | 93309 | — |
| Investigative Site | Fullerton | California | 92835 | — |
| Investigative Site | Los Angeles | California | 90095 | — |
| Investigative Site | Denver | Colorado | 80218 | — |
| Investigative Site | St. Petersburg | Florida | 33705 | — |
| Investigative Site | West Palm Beach | Florida | 33401 | — |
| Investigative Site | Atlanta | Georgia | 30318 | — |
| Investigative Site | Wichita | Kansas | 67214 | — |
| Investigative Site | Baton Rouge | Louisiana | 70809 | — |
| Investigative Site | Columbia | Maryland | 21044 | — |
| Investigative Site | Burnsville | Minnesota | 55337 | — |
| Investigative Site | Las Vegas | Nevada | 89119 | — |
| Investigative Site | Florham Park | New Jersey | 07932 | — |
| Investigative Site | Asheville | North Carolina | 28806 | — |
| Investigative Site | Columbus | Ohio | 43219 | — |
| Investigative Site | Eugene | Oregon | 97401 | — |
| Investigative Site | Portland | Oregon | 97239 | — |
| Investigative Site | Horsham | Pennsylvania | 19044 | — |
| Investigative Site | Austin | Texas | 78705 | — |
| Investigative Site | Dallas | Texas | 75246 | — |
| Investigative Site | San Antonio | Texas | 78258 | — |
| Investigative Site | Tyler | Texas | 75702 | — |
| Investigative Site | Arlington | Virginia | 22205 | — |
| Investigative Site | Norfolk | Virginia | 23502 | — |
| Investigative Site | Roanoke | Virginia | 24014 | — |
| Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06119217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2024 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06119217 live on ClinicalTrials.gov.